Part II-?Trials with Viasept and Neoviasept. P-glycolylaminophenylarsonic acid (Viasept) was first shown in 1938 to possess curative activity in experimental amcebiasis of cats (cf. Wagner, 1951) . Subsequent clinical trials were encouraging (particularly in cyst carriers) and it was at that time also stated that the drug would be suitable for prophylactic treatment owing to lack of toxic effects (Hauer, 1943)? These early reports were followed by a lar?e number of clinical investigations (Berberian, 1948, Sodeman and Beaer, 1952 , Wilmet et 1951 . Hcekenga, 1952 The investigation extended over the period
vity in experimental amcebiasis of cats (cf. Wagner, 1951) . Subsequent clinical trials were encouraging (particularly in cyst carriers) and it was at that time also stated that the drug would be suitable for prophylactic treatment owing to lack of toxic effects (Hauer, 1943) ? These early reports were followed by a lar?e number of clinical investigations (Berberian, 1948 , Sodeman and Beaer, 1952 , Wilmet et 1951 . Hcekenga, 1952 Di-iodohydroxyquinoline (5, 7?Di-iodo?S ?hydroxyquinoline) has been extensively used for treatment of amcebic colitis ever since its introduction in therapeutics in 1936 ; its effen tiveness as amcebicidal drug has recently been re-established in a series of critical "tests (Wilmet et al, 1951) 
